1 / 8

Glecaprevir - Pibrentasvir in HCV GT 1 & Prior DAA Treatment MAGELLAN-1 (Part 1)

Phase 2. Treatment-Experienced. Glecaprevir - Pibrentasvir in HCV GT 1 & Prior DAA Treatment MAGELLAN-1 (Part 1). Source: Poordad F, et al. Hepatology. 2017;66:389-97. Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA Treatment MAGELLAN-1 (Part 1) : Study Features.

zudora
Télécharger la présentation

Glecaprevir - Pibrentasvir in HCV GT 1 & Prior DAA Treatment MAGELLAN-1 (Part 1)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 Treatment-Experienced Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA TreatmentMAGELLAN-1 (Part 1) Source: PoordadF, et al. Hepatology. 2017;66:389-97.

  2. Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA TreatmentMAGELLAN-1 (Part 1): Study Features Source: Poordad F, et al. Hepatology. 2017;66:389-97.

  3. Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA TreatmentMAGELLAN-1 (Part 1): Treatment Regimens 0 12 24 Week GT 1 n = 50 Glecaprevir: 200 mgPibreantasvir: 80 mg SVR12 n = 6 Glecaprevir: 300 mgPibreantasvir: 120 mg Ribavirin: 800 mg n = 22 SVR12 Glecaprevir: 200 mgPibreantasvir: 120 mg SVR12 n = 22 Source: Poordad F, et al. Hepatology. 2017;66:389-97.

  4. Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA TreatmentMAGELLAN-1 (Part 1): Baseline Characteristics GLE-PIB= glecaprevir-pibrentasvir; RBV = ribavirin; BMI = body mass index Source: Poordad F, et al. Hepatology. 2017;66:389-97.

  5. Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA TreatmentMAGELLAN-1 (Part 1): Baseline Characteristics GLE-PIB= glecaprevir-pibrentasvir Source: Poordad F, et al. Hepatology. 2017;66:389-97.

  6. Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA TreatmentMAGELLAN-1 (Part 1): Study Design 6/6 21/22 19/22 Source: Poordad F, et al. Hepatology. 2017;66:389-97.

  7. Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA TreatmentMAGELLAN-1 (Part 1): Conclusions Source: Poordad F, et al. Hepatology. 2017;66:389-97.

  8. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related